First, some TPO-RAs have already been made available and are widely employed for ITP in clinical practice, and our trial did not use a previously approved TPO-RA as a control because no TPO-RA was approved in China during the study design. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.